Summary of analytical and clinical data for Signatera™, the first ctDNA assay custom-built for MRD detection and treatment response.
Signatera is a new blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA.
Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?
The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions.
Ococks et al. 2021 Gastroenterology
Kasi et al. 2021 BMJ Open
Oliva et al. 2021 Journal for ImmunoTherapy of Cancer
Yang et al. 2021 Nat Commun
Design and analytical validation of SignateraTM, the first ctDNA assay custom-built for detecting MRD and assessing treatment response.
Signatera is a new cancer surveillance test uniquely personalized for each patient.
Abbosh et al. 2017 Nature
Christensen et al. 2019 J. Clin. Oncol.
Reinert et al. 2019 JAMA Oncol.
Coombes et al. 2019 Clin. Cancer Res.
Einstein et al. 2020 JCO-Precision Oncology.
Magbanua et al. 2020 Annals of Oncology
Jamal-Hanjani et al. 2016 Ann Oncol.